REGENXBIO Inc. (RGNX)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
$7.40+$0.1600 (+2.21%) on the dayAs of the close; data may be delayed.
RGNX price, last 12 months
Key stats
- Previous close
- $7.24
- Open
- $7.39
- Day range
- $7.17 – $7.68
- 52-week range
- $5.46 – $16.19
- Volume
- 1M
- Avg volume (20 days)
- 1.3M
- Market cap
- $488.5M
Performance
1W−7.9%
1M−21.1%
3M−29.4%
6M−10.4%
YTD−48.6%
1Y−22.4%
vs S&P 500, 1Y−39.2 pts
Technicals and fundamentals
About REGENXBIO Inc.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $488.5M